HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study.

Abstract
Topotecan was studied as a 72 h infusion given every 3 weeks. Treatment began at a dose of 1.0 mg/m2/day and was increased to 1.25 mg/m2/day after the first 6 patients tolerated this higher dose without excessive toxicities. Eighty-eight evaluable children were accrued in 6 strata. There were no complete nor partial responses. Twenty subjects had stable disease (astrocytoma 5/11, malignant glioma 5/13, medulloblastoma 0/12, brain stem tumor 4/19, ependymoma 5/17, and miscellaneous histologies 1/16). Two patients (astrocytoma, ependymoma) completed the maximum 18 topotecan courses. The remaining 68 children developed progressive disease within 2 months. Myelosuppression was the main toxicity. Grade 4 leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 18, 32, 5, and 23 participants, respectively. It was concluded that topotecan as given according to this schedule showed insufficient activity to promote it to frontline protocol usage.
AuthorsR P Kadota, C F Stewart, M Horn, J F Kuttesch Jr, P C Burger, J L Kepner, L E Kun, H S Friedman, R L Heideman
JournalJournal of neuro-oncology (J Neurooncol) Vol. 43 Issue 1 Pg. 43-7 (May 1999) ISSN: 0167-594X [Print] United States
PMID10448870 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Topotecan
Topics
  • Adult
  • Antineoplastic Agents (adverse effects, pharmacokinetics, therapeutic use)
  • Central Nervous System Neoplasms (drug therapy, metabolism, pathology)
  • Child
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors (adverse effects, pharmacokinetics, therapeutic use)
  • Humans
  • Magnetic Resonance Imaging
  • Neoplasm Recurrence, Local (drug therapy, metabolism, pathology)
  • Tomography, X-Ray Computed
  • Topotecan (adverse effects, pharmacokinetics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: